The capital return plan (up to ~$230M, ~25% of market cap) and the Pfizer/BioNTech LNP lawsuits are the primary catalysts. Monitor for the specific form of the tender offer/buyback and any developments in the international patent litigation. The imdusiran Phase 2b alignment is a positive pipeline de-risking event.
Drug in focus
ABUS drug pipeline →imdusiran
● Neutral Named in this 8-K- Impact
- Phase
- Phase 2 (completed); Phase 2b planned
- Time to market
- Unknown — likely several years out. Phase 2b design is FDA-aligned but the trial had not been initiated as of the Aug 2026 update; a registrational Phase 3 and filing would still follow, so 2028+ at the earliest if all goes well.
- Next catalyst
- None dated
What to watchNear-term share-price drivers are the $230M Dutch-auction tender offer (expires Sept 29, 2026, at $5.00–$5.75) and the LNP patent lawsuits vs. Pfizer/BioNTech; watch for Phase 2b initiation announcements and conference data updates for imdusiran specifically.
Price Chart
Executive Summary
Arbutus Biopharma reported Q2 2026 results with a net loss of $5.1M ($-0.03 EPS) vs net income of $2.5M ($0.01 EPS) in Q2 2025, driven by the absence of the prior year's $9.6M Qilu partnership revenue recognition. The company received $178.4M from the Moderna settlement in July and announced a plan to return up to ~$230M to shareholders via share repurchases, while also filing three international LNP patent lawsuits against Pfizer/BioNTech. The stock will move on the capital return plan and the Pfizer/BioNTech litigation catalyst, not the operational quarter.
Key Financial Metrics
Key Facts
- Q2 2026 net loss of $5.1M ($-0.03 EPS) vs net income of $2.5M ($0.01 EPS) in Q2 2025
- Total revenue fell to $1.0M from $10.7M YoY due to prior-year Qilu partnership revenue recognition
- Received $178.4M from Moderna settlement in July 2026
- Plans to return up to ~$230M to shareholders via share repurchases starting Q3 2026
- Filed three international LNP patent enforcement lawsuits against Pfizer/BioNTech across 21 countries
- FDA alignment achieved on Phase 2b trial design for imdusiran in chronic hepatitis B
- Cash, cash equivalents and marketable securities of $92.6M as of June 30, 2026
Financial Impact
Up to $230M capital return to shareholders; $178.4M Moderna settlement payment received; $1.3B contingent payment possible from Moderna; Pfizer/BioNTech LNP lawsuits with unquantified potential
Risk Factors
- Capital return plan is subject to board approval and may not occur
- Pfizer/BioNTech lawsuits are early-stage and face significant legal hurdles
- Moderna contingent payment of $1.3B depends on appellate ruling on 28 U.S.C. 1498
- Operating cash burn continues ($14.1M in H1 2026)
- Imdusiran remains in clinical development with no guarantee of regulatory approval
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001171843-26-005442 |
| Document: f8k_081226.htm | 0001171843-26-005442 |
| Document: 0001171843-26-005442-index-headers.html | 0001171843-26-005442 |
| Document: 0001171843-26-005442-index.html | 0001171843-26-005442 |
| Document: 0001171843-26-005442.txt | 0001171843-26-005442 |
| 8-K Data (Synthetic) | 0001171843-26-005442 |
Track record
25 reports on ABUS
3 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +11.55% at T+20 after the Aug 12, 2026 report. 6 of 12 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $4.04 Now $4.04 −0.00% settles Feb 16
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $4.04 Now $4.04 −0.00% settles Feb 16
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $4.07 Now $4.04 −0.74% settles Feb 12
- Nov 12, 20264d ago 8-K Neutral 2/10 Entry $4.03 Now $4.04 +0.25% settles Feb 10
- Nov 10, 20266d ago 8-K Neutral 5/10 Entry $3.82 Now $4.04 +5.76% settles Feb 8
- Nov 10, 20266d ago Press Release Neutral 4/10 No price data
- Nov 6, 202610d ago Institutional Cluster Bearish 4/10 Entry $3.66 Now $4.04 −10.53% settles Feb 4
- Oct 22, 202625d ago 8-K Bullish 6/10 Entry $4.21 Now $4.04 −4.04% settles Jan 20
- Oct 22, 202625d ago Press Release Bullish 7/10 Entry $4.21 Now $4.04 −4.04% settles Jan 20
- Oct 7, 20265w ago SC 13G/A Neutral 3/10 Entry $4.18 Now $4.04 −3.35% settles Jan 5
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers